118 related articles for article (PubMed ID: 12657956)
1. Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats.
Jia D; Otsuki M
Pancreas; 2003 Apr; 26(3):286-91. PubMed ID: 12657956
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats.
Jia D; Yamamoto M; Otani M; Otsuki M
Metabolism; 2004 Apr; 53(4):405-13. PubMed ID: 15045684
[TBL] [Abstract][Full Text] [Related]
3. Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic rats.
Jia D; Taguchi M; Otsuki M
Metabolism; 2005 May; 54(5):619-27. PubMed ID: 15877292
[TBL] [Abstract][Full Text] [Related]
4. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
Kim SK; Zhao ZS; Lee YJ; Lee KE; Kang SM; Choi D; Lim SK; Chung N; Lee HC; Cha BS
Diabetes Metab Res Rev; 2003; 19(6):487-93. PubMed ID: 14648808
[TBL] [Abstract][Full Text] [Related]
5. Metabolic abnormalities in the genetically obese and diabetic Otsuka Long-Evans Tokushima Fatty rat can be prevented and reversed by alpha-glucosidase inhibitor.
Yamamoto M; Jia DM; Fukumitsu KI; Imoto I; Kihara Y; Hirohata Y; Otsuki M
Metabolism; 1999 Mar; 48(3):347-54. PubMed ID: 10094112
[TBL] [Abstract][Full Text] [Related]
6. Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats.
Jia D; Taguchi M; Otsuki M
Pancreas; 2005 Jan; 30(1):54-61. PubMed ID: 15632700
[TBL] [Abstract][Full Text] [Related]
7. Troglitazone prevents fatty changes of the liver in obese diabetic rats.
Jia DM; Tabaru A; Akiyama T; Abe S; Otsuki M
J Gastroenterol Hepatol; 2000 Oct; 15(10):1183-91. PubMed ID: 11106100
[TBL] [Abstract][Full Text] [Related]
8. A peroxisome proliferator-activated receptor gamma agonist influenced daily profile of energy expenditure in genetically obese diabetic rats.
Yoshida Y; Ichikawa M; Ohta M; Kanai S; Kobayash M; Ichimaru Y; Shimazoe T; Watanabe S; Funakoshi A; Miyasak K
Jpn J Pharmacol; 2002 Mar; 88(3):279-84. PubMed ID: 11949882
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Koh EH; Kim MS; Park JY; Kim HS; Youn JY; Park HS; Youn JH; Lee KU
Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Jia DM; Tabaru A; Nakamura H; Fukumitsu KI; Akiyama T; Otsuki M
Metabolism; 2000 Sep; 49(9):1167-75. PubMed ID: 11016899
[TBL] [Abstract][Full Text] [Related]
11. Treatment for hyperglycemia promotes pancreatic regeneration in rats without CCK-1 receptor gene expression.
Yamamoto M; Jia DM; Fukumitsu K; Otsuki M
Pancreas; 2003 May; 26(4):368-74. PubMed ID: 12717270
[TBL] [Abstract][Full Text] [Related]
12. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
[TBL] [Abstract][Full Text] [Related]
13. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.
Lee HJ; Choi SS; Park MK; An YJ; Seo SY; Kim MC; Hong SH; Hwang TH; Kang DY; Garber AJ; Kim DK
Biochem Biophys Res Commun; 2002 Aug; 296(2):293-9. PubMed ID: 12163016
[TBL] [Abstract][Full Text] [Related]
14. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
Franko A; Neschen S; Rozman J; Rathkolb B; Aichler M; Feuchtinger A; Brachthäuser L; Neff F; Kovarova M; Wolf E; Fuchs H; Häring HU; Peter A; Hrabě de Angelis M
Mol Metab; 2017 Mar; 6(3):256-266. PubMed ID: 28271032
[TBL] [Abstract][Full Text] [Related]
15. Bezafibrate-induced changes over time in the expression of uncoupling protein (UCP) mRNA in the tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.
Mori Y; Tokutate Y; Oana F; Matsuzawa A; Akahane S; Tajima N
J Atheroscler Thromb; 2004; 11(4):224-31. PubMed ID: 15356383
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
Fernandes-Santos C; Evangelista Carneiro R; de Souza Mendonca L; Barbosa Aguila M; Mandarim-de-Lacerda CA
Pancreas; 2009 Apr; 38(3):e80-6. PubMed ID: 19214135
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Tenenbaum A; Motro M; Fisman EZ; Schwammenthal E; Adler Y; Goldenberg I; Leor J; Boyko V; Mandelzweig L; Behar S
Circulation; 2004 May; 109(18):2197-202. PubMed ID: 15123532
[TBL] [Abstract][Full Text] [Related]
18. Effect of timely insulin administration on pancreatic B-cells of Otsuka-Long-Evans-Tokushima-Fatty (OLETF) strain rats. An animal model of non-insulin dependent diabetes mellitus (NIDDM).
Ishida K; Mizuno A; Sano T; Noma Y; Shima K
Horm Metab Res; 1995 Sep; 27(9):398-402. PubMed ID: 8557237
[TBL] [Abstract][Full Text] [Related]
19. [Expression of aquaporin 7 in perirenal adipose tissue of Otsuka Long-Evans Tokushima Fatty diabetic rats].
Duan Ym; Yuan Zf; Yao J; Zhang Tt; Chen C; Guo Xh
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):117-22. PubMed ID: 21321634
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone stimulates pancreatic growth in normal rats.
Jia DM; Otsuki M
Pancreas; 2002 Apr; 24(3):303-12. PubMed ID: 11893940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
